What is the ticker symbol for NuCana?

NuCana trades under the ticker NCNA on NASDAQ.

What sector does NuCana operate in?

NuCana is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NCNA in a portfolio?

PortView shows NCNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

NuCana (NCNA) Stock Analysis

NASDAQHealthcareBiotechnology

$1.37-0.72%

1-year price historyRange $1.21 – $7.02

52-week range$1.37

$1.21$7.22

What NuCana does

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.

Key metrics

Market cap

$8.32M

P/E (TTM)

-0.46

EPS (TTM)

$-2.98

Beta

2.22

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$1.42

200-day avg

$2.27

52-week high

$7.22

52-week low

$1.21

CEO

Hugh Stephen Griffith

ETFs linked to NCNA

Broad-market and Healthcare sector ETFs an investor holding NuCana is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how NCNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze NCNA in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for NuCana?: NuCana trades under the ticker NCNA on NASDAQ.
Which exchange is NCNA listed on?: NCNA is listed on NASDAQ.
What sector does NuCana operate in?: NuCana is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze NCNA in a portfolio?: PortView shows NCNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.